R‐<scp>CHOP </scp><i>versus</i> dose‐adjusted R‐<scp>EPOCH</scp> in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis
Nirav N. Shah(Medical College of Wisconsin), Jakub Svoboda(UPMC Hillman Cancer Center), Jonathon B. Cohen(Emory University), Siddhartha Ganguly(University of Kansas Medical Center), Alexandra E. Kovach(University of Southern California), Mehdi Hamadani(Medical College of Wisconsin), Ryan Okal(West Virginia University), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Lauren E. Strelec(University of Pennsylvania), Anikó Szabó(University of Wisconsin–Madison), Cynthia Obiozor(University Medical Center), Scott F. Huntington(Yale Cancer Center), Fahad Faruqi(Yale University), Abraham S. Kanate(HonorHealth), Timothy S. Fenske(Medical College of Wisconsin), Nilanjan Ghosh(Levine Cancer Institute), Julie M. Vose(University of Nebraska Medical Center), Julio C. Chávez(Moffitt Cancer Center), Nishitha Reddy(Vanderbilt University), Narendranath Epperla(University of Utah), Oscar Calzada(Emory University), Ana C. Xavier(University of Alabama at Birmingham), Luciano J. Costa(University of Alabama at Birmingham)
Cited by 101
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k